Pharmaceutical firm Kalbe Farma (KLBF) booked a net profit of Rp2.54 trillion in 2019, up 1.6% year on year (y/y), mostly supported by top-line growth, as well as marketing expense control. It booked a net revenue of Rp22.6 trillion last year, grew 4.7% y/y, while the cost of goods sold rose 10.4% to Rp12.4 trillion. Kalbe’s operating expenses also increased by 3% to Rp5.36 trillion. General and administrative expenses rose 8% to Rp1,29 trillion.

To subscribe please click here